Telbivudine

替比夫定

Report date: 2022/08/24 16:40:37
NME

Base Information

Drug NameTelbivudine
Drug Alias NameEpavudine喜必福替比呋啶telbivudinatelbivudinum +[16
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReverse transcriptase inhibitors
TargetsReverse transcriptase
Therapy Area/IndicationsLiver CirrhosisHepatitisHepatitis B, Chronic +[4
Global Approved IndicationsHepatitis B, ChronicHepatitis B
Approved Indications in ChinaHepatitis B, Chronic
Original Approved Country/TerritorySwitzerland
Original Approved Date2006/09/01
Country/TerritoryCzechiaBelgiumBulgaria +[33
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsLiver CirrhosisHepatitis

Other Information

ATC CodeJ05AF11